Lyell Immunopharma Reports Q4 Loss

Biotech firm posts $140.7 million loss in latest quarter

Mar. 12, 2026 at 10:10pm

Got story updates? Submit your updates here. ›

Lyell Immunopharma Inc., a biotechnology company based in South San Francisco, California, reported a loss of $140.7 million in its fourth quarter. The company posted revenue of $6,000 during the period.

Why it matters

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing novel T cell therapies for solid tumors. The company's financial performance is closely watched by investors and analysts as an indicator of its progress in developing new cancer treatments.

The details

On a per-share basis, Lyell Immunopharma reported a loss of $7.68. For the full year, the company reported a loss of $274.4 million, or $16.06 per share, on revenue of $36,000.

  • Lyell Immunopharma reported its Q4 and full-year 2025 financial results on March 12, 2026.

The players

Lyell Immunopharma Inc.

A clinical-stage biotechnology company focused on developing novel T cell therapies for solid tumors.

Got photos? Submit your photos here. ›

The takeaway

Lyell Immunopharma's significant losses in Q4 and for the full year 2025 highlight the challenges facing the company as it works to develop new cancer treatments. Investors will be closely watching the company's progress in the coming quarters as it seeks to advance its pipeline of experimental therapies.